Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-03-31falseNo description of principal activity2024-04-01false22truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 10067973 2024-04-01 2025-03-31 10067973 2023-04-01 2024-03-31 10067973 2025-03-31 10067973 2024-03-31 10067973 2023-04-01 10067973 c:Director1 2024-04-01 2025-03-31 10067973 d:PlantMachinery 2024-04-01 2025-03-31 10067973 d:PlantMachinery 2025-03-31 10067973 d:PlantMachinery 2024-03-31 10067973 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 10067973 d:FurnitureFittings 2024-04-01 2025-03-31 10067973 d:FurnitureFittings 2025-03-31 10067973 d:FurnitureFittings 2024-03-31 10067973 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 10067973 d:OfficeEquipment 2024-04-01 2025-03-31 10067973 d:OfficeEquipment 2025-03-31 10067973 d:OfficeEquipment 2024-03-31 10067973 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 10067973 d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 10067973 d:CurrentFinancialInstruments 2025-03-31 10067973 d:CurrentFinancialInstruments 2024-03-31 10067973 d:Non-currentFinancialInstruments 2025-03-31 10067973 d:Non-currentFinancialInstruments 2024-03-31 10067973 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 10067973 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 10067973 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 10067973 d:Non-currentFinancialInstruments d:AfterOneYear 2024-03-31 10067973 d:ShareCapital 2024-04-01 2025-03-31 10067973 d:ShareCapital 2025-03-31 10067973 d:ShareCapital 2023-04-01 2024-03-31 10067973 d:ShareCapital 2024-03-31 10067973 d:ShareCapital 2023-04-01 10067973 d:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 10067973 d:RetainedEarningsAccumulatedLosses 2025-03-31 10067973 d:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 10067973 d:RetainedEarningsAccumulatedLosses 2024-03-31 10067973 d:RetainedEarningsAccumulatedLosses 2023-04-01 10067973 c:OrdinaryShareClass1 2024-04-01 2025-03-31 10067973 c:OrdinaryShareClass1 2025-03-31 10067973 c:OrdinaryShareClass1 2024-03-31 10067973 c:FRS102 2024-04-01 2025-03-31 10067973 c:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 10067973 c:FullAccounts 2024-04-01 2025-03-31 10067973 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 10067973 2 2024-04-01 2025-03-31 10067973 e:PoundSterling 2024-04-01 2025-03-31 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 10067973







JUNIUS HEALTH LIMITED


FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
FOR THE PERIOD ENDED 31 MARCH 2025

 
JUNIUS HEALTH LIMITED
REGISTERED NUMBER: 10067973

STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
1,307
2,874

  
1,307
2,874

Current assets
  

Debtors: amounts falling due within one year
 5 
2,280
7,121

Cash at bank and in hand
 6 
5,208
11,640

  
7,488
18,761

Creditors: amounts falling due within one year
 7 
(1,554,904)
(1,451,622)

Net current liabilities
  
 
 
(1,547,416)
 
 
(1,432,861)

Total assets less current liabilities
  
(1,546,109)
(1,429,987)

Creditors: amounts falling due after more than one year
 8 
(75,000)
(75,000)

  

Net liabilities
  
(1,621,109)
(1,504,987)


Capital and reserves
  

Called up share capital 
 9 
200
200

Profit and loss account
 10 
(1,621,309)
(1,505,187)

  
(1,621,109)
(1,504,987)


Page 1

 
JUNIUS HEALTH LIMITED
REGISTERED NUMBER: 10067973
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 3 October 2025.




Paula Collins
Director

The notes on pages 4 to 8 form part of these financial statements.

Page 2

 
JUNIUS HEALTH LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 MARCH 2025


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 April 2023
200
(1,397,416)
(1,397,216)


Comprehensive income for the year

Loss for the year
-
(107,771)
(107,771)
Total comprehensive income for the year
-
(107,771)
(107,771)


Total transactions with owners
-
-
-



At 1 April 2024
200
(1,505,187)
(1,504,987)


Comprehensive income for the period

Loss for the period
-
(116,122)
(116,122)
Total comprehensive income for the period
-
(116,122)
(116,122)


Total transactions with owners
-
-
-


At 31 March 2025
200
(1,621,309)
(1,621,109)


The notes on pages 4 to 8 form part of these financial statements.

Page 3

 
JUNIUS HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
1.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
1.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
1.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
1.5

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
JUNIUS HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025

1.Accounting policies (continued)

 
1.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
10%
Fixtures and fittings
-
25%
Office equipment
-
25%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
1.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
1.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 5

 
JUNIUS HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025

2.


Judgments in applying accounting policies and key sources of estimation uncertainty

In the application of the company's accounting policies management is required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily ascertainable from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual outcomes may differ from these estimates.
The estimates and underlying assumptions are reviewed on a continuing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised.
The key areas of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described below:
Prepayments & Accrued Expenditure
The company includes a provision for invoices which are yet to be received from and amounts paid in advance to suppliers. These provisions are estimated based upon the expected values of the invoices which are issued and services received following the period end.


3.


Employees

The average monthly number of employees, including directors, during the period was 2 (2024 - 2).


4.


Tangible fixed assets





Plant and machinery
Fixtures and fittings
Office equipment
Total

£
£
£
£



Cost or valuation


At 1 April 2024
12,710
300
2,108
15,118



At 31 March 2025

12,710
300
2,108
15,118



Depreciation


At 1 April 2024
10,168
300
1,776
12,244


Charge for the period on owned assets
1,271
-
296
1,567



At 31 March 2025

11,439
300
2,072
13,811



Net book value



At 31 March 2025
1,271
-
36
1,307



At 31 March 2024
2,542
-
332
2,874

Page 6

 
JUNIUS HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025

5.


Debtors

2025
2024
£
£


Trade debtors
1,269
587

Other debtors
1,011
6,534

2,280
7,121



6.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
5,208
11,640

5,208
11,640



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
6
-

Corporation tax
-
3,829

Other taxation and social security
1,493
1,910

Other creditors
1,551,905
1,444,383

Accruals and deferred income
1,500
1,500

1,554,904
1,451,622



8.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Amounts owed to joint ventures
75,000
75,000

75,000
75,000


Page 7

 
JUNIUS HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025

9.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



200 (2024 - 200) Ordinary shares of £1.00 each
200
200



10.


Reserves

Profit and loss account

The profit and loss reserve is fully distributable.


11.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £1,146 (2024 - £1,264). Contributions totalling £249 (2024 - £257) were payable to the fund at the reporting date and are included in creditors.

 
Page 8